Qualiber, Inc., had been a spin-off from UNC-Chapel Hill, School of Pharmacy developing therapeutics using a novel drug delivery nanotechnology (nanoCLIPD) that has the potential to transform existing (previously FDA approved) therapeutics across multiple disease areas. Developing nanotechnologies to solve drug delivery challenges for nucleic acid-based therapeutics, such as DNA and mRNA, with a focus on cancer, hepatitis and liver diseases, the company also saddressed delivery challenges for innovative siRNA, small molecules & gene based therapeutics. By 2016, both princpals of the firm appear to havemoved toother opportunities.
